Table 2. Validation cohort characteristics.
Number | 58 |
---|---|
Mean age | 61 |
Mean PSA | 6.9 |
Mean follow-up (months) | 57 |
Gleason | |
3+3 | 11 (19%) |
3+4 | 35 (60%) |
4+3 | 8 (14%) |
4+4 | 1 (2%) |
4+5 | 3 (5%) |
Stage | |
T2 | 2 |
T2a | 1 |
T2b | 44 |
T3a | 8 |
T3b | 3 |
PSA recurrence | 14 (24%) |
Lymph nodes (+) | 40 (69%) |
Surgical margins (+) | 5 (9%) |
Extracapsular extension | 11 (19%) |
Seminal vesicle (+) | 4 (7%) |
Hypermethylated tumour | 46 (83%) |